Crinetics Pharmaceuticals’ $350 Million Public Offering of Common Stock

Pietro Martinoia
Tagged:

Latham & Watkins advised Crinetics, and Cooley advised the underwriters on the offering.Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced the pricing of an upsized underwritten public offering…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Pietro Martinoia

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here